Search Results 261-270 of 17409 for Mmol

1. Return of Actionable Variants Empirical - Mayo Clinic

   ... mmol/L in LDL cholesterol [approximately 1 SD of the trait distribution]). These data suggest that multiple common alleles of small effect can make ...

2. Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) - Mayo Clinic

   Hemoglobin < 8 g/dL (5 mmol/L at randomization, no ongoing bleeding, no blood transfusion of whole blood or red blood cells within 24 hours); however, for ...

3. NBTXR3 With or Without Cetuximab LA-HNSCC - Mayo Clinic

   ... mmol/L) if the participant is a candidate for cetuximab treatment as per the Investigator's choice prior to randomization. Exclusion Criteria: -HNSCC ...

4. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

   Hgb ≥ 8 g/dL or ≥ 4.96 mmol/L;; Platelet count ≥ 100,000 platelets/mm^3 (untransfused);; Total bilirubin ≤ 1.5× ULN;; AST ≤ 3× ULN and ALT ≤ 3× ULN ...

5. Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma - Mayo Clinic

   Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L); Serum calcium ≤ 10.9 mg/dL; Negative pregnancy test done ≤ 72 hours prior to starting drug, for women of ...

6. Efficacy and Safety of Seralutinib in Adult Subjects With PAH - Mayo Clinic

   Bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (20 g/L or greater) or more, or v. Bleeding leading to a transfusion of 2 U or more of whole ...

7. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma - Mayo Clinic

   ≥ 9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment). Renal. Serum creatinine OR Measured or calculated* creatinine ...

8. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   Hemoglobin ≥ 8 g/dL or ≥ 5.6 mmol/L. Platelets ≥ 100 x10^9 /L (not achieved by transfusion). Creatinine clearance ≥ 40 mL/min. Participants who are ...

9. Macroglobulinemia Clinical Trials - Mayo Clinic Research

   Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...

10. https://www.mayoclinic.org/spanish_procedure_concepts.xml